Xenolith Medical

Oct 14, 2015

XENIA AND US-BASED VLSI INVEST NIS 3.7 MILLION IN XENOLITH 02/01/2011 Kiryat Gat, Israel – January 2, 2011 – Xenia Venture Capital (TASE:XENA) announced today the signing of an investment agreement between Xenia and Xenolith Medical Ltd. Xenolith is developing a ureteroscopic device designed to prevent renal stone migration to the kidneys following their disintegration during laser ureteroscopy procedures while collecting residue thereof. The Virginia Life Sciences Investment Fund (VLSI), which cooperates extensively with Xenia in a number of medical device portfolio companies, will invest $500,000 in Xenolith. According to Anat Segal, CEO of Xenia: “We are happy to add a promising company such as Xenolith to our investment portfolio and believe that, similarly to our other medical device companies, it will create value for Xenia’s shareholders. I would like to stress that VLSI, which specializes in investing in medical device companies and has pushed forward many of our companies, is a very significant force for Xenolith’s future.” Xenia will invest in Xenolith approximately NIS 1.9 million, NIS 1.7 million of which constitute a government loan. According to the agreement, Xenia will hold 27.50 percent of Xenolith’s shares, fully diluted. In addition to Xenia, US-based investment fund VLSI, which specializes in investing in medical device companies, will invest 500,000 dollars in Xenolith. So far, VLSI has invested in four of Xenia’s portfolio companies. Xenolith’s ureteroscopic device is expected to provide for a more efficient, safer and quicker procedure than in existence today. Renal stones and urinary tract stones occur in 5-7 percent of women and 10-12 percent of men worldwide, i.e., 5 million new cases are diagnosed each year. About Xenia Venture Capital: Xenia Venture Capital (TASE: XENA) is a publically traded investment company which operates a privatized technological incubator. Xenia Venture Capital specializes in investments in companies and start-ups in the fields of medical devices and IT. Among Xenia’s founders and main shareholders are the Novacom Group, controlled by Avishay Noam and H. Mer Industries, Anat Segal (CEO), as well as leading high-tech figures and institutional investors. Xenia’s Board of Directors and Advisory Board comprise highly successful business entrepreneurs, members of Israel’s high-tech elite, such as Dr. Orna Berry, Mr. Avi Lior, Mr. Roni Einav, Mr. Aki Ratner, Mr. Gideon Mantel, Dr. Yafit Stark, Prof. Yossi Shaham, and others. Xenia’s goal is to jump-start and support entrepreneurs so as to increase their chances of success in world markets and enhance the realization of their companies’ business potential. Since its establishment at the end of 2003, Xenia Venture Capital has invested in twenty companies, many of which have completed follow-on investments and have gone on to launch their sales efforts and form valuable international partnerships. Leading IT portfolio companies include, among others, Correlix, Arcos, BandWD, AdYouNet, Superfish, M-Photo, Intuview, and Playcast. In the medical devices field, Xenia has invested in BioProtect, PolyPid, NeatStitch, Medi-tate, ActiVein, NexSig, Slimedics, Xenolith and Ortho-Space, among others. © Xenia Venture Capital 2012 All Rights Reserved